Prognostic significance of copy number gains of MYC detected by fluorescence in situ hybridization in large B-cell lymphoma
The MYC protooncogene plays a critical role in many cellular processes. MYC translocations are recurrent in large B-cell lymphomas (LBCLs) where they exhibit a negative effect on survival. Gain of MYC copies is also frequently identified; however, there is no consensus on the frequency and prognostic significance of MYC copy gains. We collected FISH data for MYC with reflex testing for BCL2 and BCL6 and IHC results at diagnosis for a cohort of 396 de novo and transformed LBCL cases and compared progression-free (PFS) and overall survival (OS) to determine the prognostic impact of extra MYC copies. The prevalence of cases with MYC copy number gain was 20.9%. PFS was shorter for patients with ≥5 MYC copies compared to controls (p = 0.0005, HR = 2.25). .MYC gain trended towards worse OS; patients with ≥7MYC copies had worse OS (p = 0.013), similar to patients with MYC translocations. We propose that MYC gain represents a dose-dependent prognostic factor for LBCLs.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:65 |
|---|---|
| Enthalten in: |
Leukemia & lymphoma - 65(2024), 1 vom: 11. Jan., Seite 26-36 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zak, Taylor [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Copy number |
|---|
| Anmerkungen: |
Date Completed 12.01.2024 Date Revised 12.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/10428194.2023.2264429 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362885125 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362885125 | ||
| 003 | DE-627 | ||
| 005 | 20240114234234.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/10428194.2023.2264429 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1257.xml |
| 035 | |a (DE-627)NLM362885125 | ||
| 035 | |a (NLM)37794791 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zak, Taylor |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Prognostic significance of copy number gains of MYC detected by fluorescence in situ hybridization in large B-cell lymphoma |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.01.2024 | ||
| 500 | |a Date Revised 12.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The MYC protooncogene plays a critical role in many cellular processes. MYC translocations are recurrent in large B-cell lymphomas (LBCLs) where they exhibit a negative effect on survival. Gain of MYC copies is also frequently identified; however, there is no consensus on the frequency and prognostic significance of MYC copy gains. We collected FISH data for MYC with reflex testing for BCL2 and BCL6 and IHC results at diagnosis for a cohort of 396 de novo and transformed LBCL cases and compared progression-free (PFS) and overall survival (OS) to determine the prognostic impact of extra MYC copies. The prevalence of cases with MYC copy number gain was 20.9%. PFS was shorter for patients with ≥5 MYC copies compared to controls (p = 0.0005, HR = 2.25). .MYC gain trended towards worse OS; patients with ≥7MYC copies had worse OS (p = 0.013), similar to patients with MYC translocations. We propose that MYC gain represents a dose-dependent prognostic factor for LBCLs | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Large B-cell lymphoma | |
| 650 | 4 | |a copy number | |
| 650 | 4 | |a mYC | |
| 650 | 7 | |a Proto-Oncogene Proteins c-myc |2 NLM | |
| 650 | 7 | |a Proto-Oncogene Proteins c-bcl-2 |2 NLM | |
| 650 | 7 | |a Proto-Oncogene Proteins c-bcl-6 |2 NLM | |
| 700 | 1 | |a Santana-Santos, Lucas |e verfasserin |4 aut | |
| 700 | 1 | |a Gao, Juehua |e verfasserin |4 aut | |
| 700 | 1 | |a Behdad, Amir |e verfasserin |4 aut | |
| 700 | 1 | |a Aqil, Barina |e verfasserin |4 aut | |
| 700 | 1 | |a Wolniak, Kristy |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Xinyan |e verfasserin |4 aut | |
| 700 | 1 | |a Ji, Peng |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Qing |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Yi-Hua |e verfasserin |4 aut | |
| 700 | 1 | |a Karmali, Reem |e verfasserin |4 aut | |
| 700 | 1 | |a Sukhanova, Madina |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Leukemia & lymphoma |d 1989 |g 65(2024), 1 vom: 11. Jan., Seite 26-36 |w (DE-627)NLM012624047 |x 1029-2403 |7 nnns |
| 773 | 1 | 8 | |g volume:65 |g year:2024 |g number:1 |g day:11 |g month:01 |g pages:26-36 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/10428194.2023.2264429 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 65 |j 2024 |e 1 |b 11 |c 01 |h 26-36 | ||